The Lancet· Amit Goel, Sumit Rungta, Vinod Kumar, Shalimar, Ajay Kumar, Harshita Katiyar, Surender Singh, Amar Deep, Ajay Kumar Mishra, Ashish Awasthi, Vikasendu Agarwal, Anurag Kumar Tiwari, Dawesh Prakash Yadav, Sunit Kumar Shukla, Ujjwal Sonika, Radha Krishan Dhiman, Bharat Bhushan Rewari, Rakesh Aggarwal·· 2026-10-01精选AI 评分60
印度RESOLVE试验:索磷布韦维帕他韦8周方案治疗慢性丙肝不劣于12周
[Articles] 8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India
AI 导读
在印度开展的多中心、开放标签、非劣效随机对照试验RESOLVE显示,索磷布韦维帕他韦8周方案治疗无肝硬化的初治慢性HCV感染,疗效与标准12周方案相似。这一结果支持在此类患者中缩短治疗时长。
推荐理由
在印度开展的多中心随机对照试验显示,8周索磷布韦维帕他韦方案与12周标准疗程疗效相近,为缩短无肝硬化HCV患者疗程提供了直接证据。
来源:The Lancet · thelancet.com